01
Target in blood
Drug molecules circulate in a small venous blood sample.
Precision sensing in venous blood
Real-timedrug diagnostics platform
Next-gen diagnostics for precision medicine. Every second counts.
Explore the platform
Products / 01
AptaSense
Point of Care Testing Analyzer
Our first assays focus on Vancomycin therapeutic drug monitoring and IL-6 detection, powered by cutting-edge aptamer-based technology.
4 Simple Steps
1
Select a single-use test strip.
2
Insert it into the analyzer.
3
Apply a small sample of patient’s venous blood.
4
Get result in just 60 seconds.
AptaSense is designed as a scalable diagnostic platform. With every new assay added to our portfolio, the same analyzer becomes capable of performing more tests, continuously increasing its clinical value over time.
Single-use test strips
Created with everyday hospital reality in mind, these strips are part of a vision to make therapeutic monitoring fast, intuitive, and accessible wherever it’s needed most.
Designed for Healthcare Leaders
We empower diagnostic laboratories and hospitals with tools that simplify processes and accelerate clinical insights.
Technology / Mechanism
How Aptamer-Based Sensing Works
Aptamedica uses aptamer-based sensing to recognize drug molecules in venous blood and translate molecular binding into a measurable diagnostic readout.
02
Aptamer interface
Selective aptamers are immobilized on the sensor surface.
03
Selective binding
The target drug is captured by its molecular recognition site.
04
Conformational change
Binding reshapes the aptamer and changes the sensor interface.
05
Diagnostic readout
The molecular event is translated into a measurable signal.
Products / 02
AptaFlow
Technology allows for more
01
Real-time precision
Continuous drug level measurement for up to 6 hours, optimizing treatment in critical care.
02
Seamless integration
Designed for hemodialysis circuits, enabling bedside therapeutic drug monitoring.
03
Redefining precision medicine
Continuous, real-time drug monitoring tailored to each patient’s unique metabolism.
About us
The people building Aptamedica.
Maciej is a Biophysicist and PhD candidate at the Krakow University of Technology. He leads Aptamedica's business strategy, product development, and commercialization. His background combines scientific research with startup execution, including fundraising, technology transfer, and building partnerships with hospitals, industry, and investors to bring innovative diagnostics to market.
Maciej Łach
CEO
Mateusz is a Biophysicist and PhD candidate at the Jagiellonian University, specializing in biosensors, electrochemical diagnostics, and analytical technologies. He leads the technological development of AptaSense, overseeing biosensor design, assay development, and laboratory validation. His work focuses on transforming cutting-edge research into scalable diagnostic solutions suitable for real-world clinical use.
Mateusz Fil
CTO
Kamil is a medical doctor and graduate of the Jagiellonian University Medical College, with frontline clinical experience in emergency medicine. He leads the clinical strategy of Aptamedica, ensuring that every product is designed around real healthcare needs, clinical workflows, and regulatory requirements. He works closely with hospitals and physicians to translate unmet clinical challenges into practical diagnostic solutions.
Kamil Pawełkiewicz
Medical DirectorAdvisors
Experience around the table.
Patryk Mikucki, DVM, PhD, MBA is a pharmaceutical executive with over 25 years of experience in clinical development and life sciences. Having held senior leadership positions at Alexion and AstraZeneca, he has led international clinical research programs and strategic R&D initiatives across Europe. He brings deep expertise in clinical development, regulatory strategy, and translating innovative technologies into clinical practice.
Patryk Mikucki
Product Development Advisor
Monika Borowiecka is Managing Partner at Tangent Line Ventures, entrepreneur, investor, and board member of multiple technology companies. Recognized among the Top 100 Women in VC in CEE and by Forbes Women, she brings more than 20 years of experience in business strategy, venture capital, sales, and marketing.
Monika Borowiecka
Venture Advisor
Piotr Pietrzak is an expert in venture capital and private equity investments with a strong track record of supporting deep-tech startups. He has helped portfolio companies scale through business development, fundraising, IPOs, and successful exits. He currently serves as Managing Partner at Tangent Line Ventures.
Piotr Pietrzak
Investor Relations AdvisorFor investors
Development pipeline
A clear view of completed work, current priorities, and the milestones ahead.
20241
Company Foundation
- Company established
- First AptaSense prototype developed
- Initial internal proof-of-concept testing
- Patentability assessment completed
20252
Technology Validation
- Clinical partner hospitals secured
- International Medical Advisory Board established
- Technology presented at international conferences
- First commercial licensing agreement signed (non-exclusive)
- International clinical references obtained
2026–20273
Preclinical Validation
- Collaborative preclinical studies with leading European hospitals
- Assay optimization and engineering iterations
- Performance validation on clinical samples
- Clinical-ready prototype by Q4 2027
2028–20304
Clinical & Regulatory
- Multi-center clinical studies
- IVDR clinical performance evaluation
- CE-IVDR certification process
- Manufacturing scale-up
20305
Commercial Launch
- First commercial production
- European market launch
- Initial hospital deployments
Future6
Platform Expansion
- Next-generation diagnostic assays
- Expanded therapeutic drug monitoring (TDM) portfolio
- Sepsis and critical care biomarkers
- Global commercialization
News
What’s happening at Aptamedica
Updates
Company updates will appear here soon.
Contact
Let's Build the Future of Diagnostics
01
Invest
Support the next generation of point-of-care diagnostics.
- Venture Capital & Angel Investors
- Strategic Investment Opportunities
02
Collaborate
Help us validate and improve our diagnostic technologies.
- Hospitals & Healthcare Providers
- Research Institutes & Clinical Partners